tebu-bio.com

October 2016

New test systems for Biopharmaceutical development

Purified hepatic lysosomes show superior lysosomal enzymatic activity when compared to liver homogenate or S9 fraction, and are more predictive than individual purified proteins when trying to cost-effectively evaluate lysosomal stability for development of ADCs, siRNA/RNAi molecules, immunotherapeutics, biodegradable copolymers and nanoparticles, etc..

Discover Human Hepatic Lysosomes and download the case study

Solute Carrier (SLC) Transporter studies...
made easy

Ready-to-use cell lines for studying MATE, OATP1B1, B3, etc without the need of license fees, royalties, complex logistic solutions, etc...

See how TRANS i PORT makes SLC studies easier

New concept for toxicology studies with Microfluidics

In this article, we demonstrate the feasibility of creating a multi-organ system capable of testing for the ability of a human liver cell line to activate a panel of chemotherapeutic drugs. We tested seven chemotherapeutic drugs for their ability to kill human MCF7 cells both with and without bioactivation by metabolically competent human HepaRG cells.

Toxicity assessment of Co-culture Human Systems

Joint DMDG/GMP Open Meeting 2016

"Back to Le Futur of Drug Metabolism and Dispositions"
19 - 21 October - Espace St Martin - Paris - France

Meet Frédéric Delteil and Jean-François Têtu to discuss our poster "Toxicity assessment of co-culture Human systems during Multi-well gradient exposures".
We'll also be introducing the new Human Liver Lysosomes (see above) at our booth.

Looking forward to meeting you there!

Choose your topics! Subscribe to tebu-bio's newsletters on your favourite research themes